Guardant Health, Inc. (NASDAQ:GH) director Tariq Musa completed a stock transaction on June 22, 2026, disposing of 1,951 shares of the company's common equity. The sale was executed at a price of $131.16 per share, generating a total proceeds amount of $255,893. Post-transaction, Mr. Musa maintains a direct position of 11,048 shares in Guardant Health.
The timing of this insider divestment coincides with Guardant Health trading near its 52-week high of $135.00. Over the past year, the stock has generated a return of 165%. According to InvestingPro analysis, the current valuation of the stock appears overvalued relative to its Fair Value estimate. This assessment places Guardant Health among companies listed on the Most Overvalued list, highlighting a divergence between recent price performance and intrinsic valuation metrics.
Concurrently, Guardant Health has achieved notable regulatory and clinical milestones. The company's Guardant360 CDx test received FDA approval as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS. This approval enables the identification of patients with specific HER2 mutations who may benefit from the treatment, representing a significant advancement in personalized medicine.
Following this regulatory development, Mizuho raised its price target for Guardant Health to $175, maintaining an Outperform rating. The firm cited the FDA approval and the American Cancer Society's recommendation of the company's Shield blood test for colorectal cancer screening as key factors supporting its outlook.
Additional analyst coverage further underscores confidence in the company's trajectory. RBC Capital initiated coverage with an Outperform rating and a price target of $185. Goldman Sachs began coverage with a Buy rating and a price target of $165, highlighting the FDA approval of the G360 CDx 740-gene panel and other growth drivers. Wolfe Research also initiated coverage with an Outperform rating and a price target of $150, noting the growth potential of the company's oncology tests.
Recent market data shows Guardant Health closing at $130.84, up $2.01 or 1.56%. After-hours trading saw the stock at $131.00, up $0.17 or 0.13%. These developments highlight the growing confidence among analysts in Guardant Health's future prospects, even as insider activity and valuation metrics present a complex picture for investors.